Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志
中国生物工程杂志  2013, Vol. 33 Issue (1): 128-135    
专题     
从Myriad案谈基因专利的正当性及美国对基因专利授权实质性要件分析
曹丽荣
华东政法大学知识产权学院 上海 201620
Analysis of the Justification for Gene Patent and Its Substantial Requirements in Patent Examination of America with the Myriad Case as Exemple
CAO Li-rong
School of Intellectual Property, East China University of Politics and Law, Shanghai 201620, China
 全文: PDF(489 KB)   HTML
摘要： 按照专利制度构建的本质,基因专利的作用在于激励产业创新,促进基因研究的发展。但基因专利从产生以来就一直存在着争议。2011年美国Myriad案对分离DNA序列的可专利性具有不同的观点,从Myriad I案认为分离的DNA是不可专利的客体,到Myriad II上诉案中联邦巡回上诉法院推翻地方法院的观点,认为分离的DNA具有不同的化学结构,满足专利客体的适格性,但同时也反射出了对DNA序列可专利性的怀疑。Myriad案引起了美国、欧洲和澳大利亚司法审判中就基因专利适格性问题的较大争议。本文结合美国Myriad案来分析DNA序列作为专利客体的适格性以及目前美国对基因专利授权的实质性条件。
关键词： 基因专利;  DNA序列;  客体适格性;  实质性条件    
Abstract: In regard to the nature of the patent law, the aim of gene patent is to promote the gene research and its related technological innovation as well. However, the issue of gene patent has been controversial since its advent. Especially,The Myriad patents have prompted strong reaction in the jurisdiction of America, Europe as well as Australia. It is not uncommon that the 2011 Myriad case in America then brought about different points of view concerning the isolated DNA sequence. The district court held that Myriad’s composition claims to "isolated" DNA molecules cover patent-ineligible products of nature under §101 since the molecules as claimed do not exist in nature. However United States Court of Appeals Federal Circuit reversed the district court’s decision and held that isolated DNA molecules qualified as patentable subject matter because the claim is not to a hitherto unknown natural phenomenon, but to a nonnaturally occurring manufacture or compositon of matter——a product of human ingenuity "having a distinctive name, character and use". But it still reflects a state of uncertainty on patentability of isolated DNA. This paper then justifies gene patent and analyzes substantial requirements of gene patent in patent examination of America.
Key words: Gene patent    DNA sequences    Subject matter eligibility    Substantial requirements of gene patent
收稿日期: 2012-10-08 出版日期: 2013-01-25
ZTFLH:  Q78  
基金资助: 上海市哲学社会科学青年项目(xm432373);上海教委科研创新青年项目(13YS079);上海市教委第五期重点学科民法与知识产权(J51104)
通讯作者: 曹丽荣     E-mail: lrongc@gmail.com
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
曹丽荣

引用本文:

曹丽荣. 从Myriad案谈基因专利的正当性及美国对基因专利授权实质性要件分析[J]. 中国生物工程杂志, 2013, 33(1): 128-135.

CAO Li-rong. Analysis of the Justification for Gene Patent and Its Substantial Requirements in Patent Examination of America with the Myriad Case as Exemple. China Biotechnology, 2013, 33(1): 128-135.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/    或    https://manu60.magtech.com.cn/biotech/CN/Y2013/V33/I1/128

[1] 张靖,张平.基因测试机构的垄断:BRCA1与BRCA2基因专利的命运.科技与法律,2010,88(6):10-14. Zhang J, Zhang P.Science Technology and Law.2010,88(6):10-14.
[2] 耿卓.知识产权发展新趋势:对研发投资保护的加强——以生物技术研究中投资的专利法保护为例.电子知识产权,2009,7:42-45. GengZh.Electronics Intellectual Property,2009,7:42-45.
[3] Adriane S. Uncommon genes unpatentable subject matter. Seattle University Law Review. 2011, 34: 909-934.
[4] 赵雷.美国2011年专利法第一案Myriad案评——人类基因可专利性的再思考.知识产权, 2012, 6: 89-95. Zhao L. A Review of the Top1 U.S.Patent Case in 2011:Rethinking the Patentability of Human Gene.Intellectual Property,2012, 6: 89-95.
[5] Gregory C. Ellis emerging biotechnologies demand defeat of proposed legislation that attempts to ban gene patents. Richmond Journal of Law & Technology, 2008, XV (1), available at: http://jolt.richmond.edu/v15i1/article1.pdf
[6] Kali M, Esther van zimmeren Dynamic patent governance in Europe and The United States: The Myriad example. Cardozo Journal of International and Comparative Law, 2011, 19: 287-341.
[7] Stephen H. Schilling DNA as patentable subject matter and a narrow framework for addressing the perceived problems caused by gene patent. Duke Law Jaurnal. 2011, 12(61): 731-773.
[8] 郑胜利,刘江彬译著.Martin J A, Randall R R, Gordon P.Klancnik, 译者.美国专利法. 知识产权出版社, 2011.
[9] 祁志.打开基因技术专利之门的案例——对Diamond v. Chakrabarty案的剖析. 《医学与哲学(人文社会医学版)》,2006,6:51-55. Qi Zh.The Case of Opening the Door for Gene-related Technologies: analysis of the case "Diamond v. Chakrabarty".Medicine and Philosophy( Humanistic & Social Medicine Edition),2006,6:51-55.
[10] Eighth Edition.Manual of Patent Examining Procedure (MPEP). http://www.uspto.gov/web/offices/pac/mpep/index.htm.
[11] Utility Examination Guidelines,http://law.shu.edu/Students/academics/journals/law-review/Issues/archives/upload/Esoy.pdf
[12] Carolina R R. Promoters Used to Regulate Gene Expression http://www.cambia.org/daisy/promoters/3141/version/default/part/AttachmentData/data/patentlens_techlandscape_promoters.pdf
[13] 张向东,张晨.在华制药领域专利技术资源竞争——美国制药企业专利资源竞争比较及其启示.中国软科学, 2006, 5:63-72. Zhang Q D, Zhang Ch.Patent Technology Resource Competition between US Drug Companies’ in China:An Empirical Comparison and Its Implications.China Soft Science,2006, 5:63-72.
[14] Steven M P, Daniel S M, Christopher T,et al. How to improve R&D productivity: The pharmaceutical Industry's grand challenge. Nature Reviews Drug Discovery, 2010, 9:203-214.
[15] Larry A R, Myriad: How Did Public Policy Weigh In?, Intell. Prop. Strategist, 2010, 5: 1-5.
[16] SACGHS Statement to the Secretary’s Advisory Committee on Genetics, Health and Society. http://www.cap.org/apps/docs/advocacy/comments/SACGHS_comments_gene_patents.pdf.
[17] Mich. T,Tech. L R.Wolrad Prinz zu Waldeck und Pyrmont, Research Tool Patents After Integra v. Merck - Have They Reached a Safe Harbor. 2008, 14: 367- 372.
[18] Christopher M. Holman, Gene Patents Under Fire: Weighing the Costs and Benefits. http://papers.ssrn.com/sol3/papers.cfm.abstract_id=1710150.
[19] Martin L. Katz, Lisa V. Mueller, Mark Polyakov & Steven F. Weinstock, Where Have All the Antibiotic Patents Gone?, Nature Biotechnology. 2006, 24:1529.
[20] Arti K R, Jerome H R, Paul F. Uhlir & Colin Crossman, Pathways Across the Valley of Death: Novel Intellectual Property Strategies for Accelerated Drug Discovery, Yale J. Health Policy L. & Ethics, 2008, 8(1): 53-89.
[21] Subhashini C, Sapna K, Cory M. Valley & Arti Rai. Proprietary science, open science, and the role of patent disclosure: the case of Zinc-Finger proteins, 27 Nature Biotechnology, 2009, 27:140-144.
[22] Dov G. New rules, different risk: The changing freedom to operate analysis for Biotechnology. North Carolina Journal of Law & Technology, 2010, 11:139-160.
[23] Yusuke H. Problems regarding the patentability of genomics and scope of protection of ESTs in Japan, CASRIP Newsletter, Winter 2000 at 17.
[1] 杨仑,夏振华,陈剑,毛颖,徐朗莱. 中国基因专利的数据挖掘[J]. 中国生物工程杂志, 2006, 26(11): 91-96.
[2] 陶然, 杨朝晖, 曾光明, 邓恩建, 李晨. 微生物絮凝剂产生菌的筛选、鉴定及其培养条件的优化研究[J]. 中国生物工程杂志, 2005, 25(8): 76-81,86.
[3] 李玉栋, 孙骞, 张春平, 张光寅. DNA自动测序技术进展[J]. 中国生物工程杂志, 1999, 19(5): 67-71.
[4] MarcWelt, 沈孝宙. DNA序列分析的若干新技术[J]. 中国生物工程杂志, 1992, 12(3): 1-6.
[5] 曾祎青, 吴鹤龄. 报告基因——哺乳类动物遗传学研究的新工具[J]. 中国生物工程杂志, 1992, 12(3): 6-14.
[6] MarcWelt, 沈孝宙. DNA序列分析的若干新技术[J]. 中国生物工程杂志, 1992, 12(3): 1-6.
[7] 曾祎青, 吴鹤龄. 报告基因——哺乳类动物遗传学研究的新工具[J]. 中国生物工程杂志, 1992, 12(3): 6-14.
[8] MarioR.Capecchi, 许罕华. 通过同源重组改变基因组[J]. 中国生物工程杂志, 1991, 11(2): 47-52.
[9] 邵惠训. 聚合酶链反应及其在病毒学工作中的应用[J]. 中国生物工程杂志, 1990, 10(6): 62-63.
[10] 沈英, 齐义鹏, 黄永秀. RNA序列测定始末[J]. 中国生物工程杂志, 1990, 10(3): 46-49.
[11] 李敏. Y染色体特异DNA序列及应用[J]. 中国生物工程杂志, 1989, 9(6): 38-41.
[12] 李其梁. 关于经典遗传学中的基因和分子遗传学中的基因[J]. 中国生物工程杂志, 1989, 9(2): 15-19.
[13] 莫鑫泉. 人基因组的结构(续)[J]. 中国生物工程杂志, 1988, 8(6): 18-29.
[14] EleanorRoosevelt, 高法恬, 莫鑫泉. 人基因组的结构[J]. 中国生物工程杂志, 1988, 8(5): 45-51.
[15] 罗静初, 唐汶. 核酸和蛋白质一级结构序列的计算机分析[J]. 中国生物工程杂志, 1988, 8(4): 28-37.
主管：中国科学院 　主办：中国科学院文献情报中心 　中国生物技术发展中心 　中国生物工程学会